Equillium (EQ) Competitors $0.42 -0.01 (-1.40%) Closing price 04:00 PM EasternExtended Trading$0.43 +0.01 (+3.35%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EQ vs. MDCX, NBRV, APLT, PLUR, PRLD, MURA, ATNM, SCLX, GRCE, and XCURShould you be buying Equillium stock or one of its competitors? The main competitors of Equillium include Medicus Pharma (MDCX), Nabriva Therapeutics (NBRV), Applied Therapeutics (APLT), Pluri (PLUR), Prelude Therapeutics (PRLD), Mural Oncology (MURA), Actinium Pharmaceuticals (ATNM), Scilex (SCLX), Grace Therapeutics (GRCE), and Exicure (XCUR). These companies are all part of the "pharmaceutical products" industry. Equillium vs. Its Competitors Medicus Pharma Nabriva Therapeutics Applied Therapeutics Pluri Prelude Therapeutics Mural Oncology Actinium Pharmaceuticals Scilex Grace Therapeutics Exicure Medicus Pharma (NASDAQ:MDCX) and Equillium (NASDAQ:EQ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment. Does the media refer more to MDCX or EQ? In the previous week, Medicus Pharma had 2 more articles in the media than Equillium. MarketBeat recorded 3 mentions for Medicus Pharma and 1 mentions for Equillium. Medicus Pharma's average media sentiment score of 1.09 beat Equillium's score of 0.40 indicating that Medicus Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Equillium 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is MDCX or EQ more profitable? Medicus Pharma has a net margin of 0.00% compared to Equillium's net margin of -19.62%. Equillium's return on equity of -74.34% beat Medicus Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Medicus PharmaN/A -380.03% -224.22% Equillium -19.62%-74.34%-46.75% Do analysts rate MDCX or EQ? Medicus Pharma presently has a consensus price target of $23.50, indicating a potential upside of 655.63%. Equillium has a consensus price target of $3.00, indicating a potential upside of 622.72%. Given Medicus Pharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Medicus Pharma is more favorable than Equillium.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Equillium 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do institutionals & insiders have more ownership in MDCX or EQ? 27.1% of Equillium shares are owned by institutional investors. 11.2% of Medicus Pharma shares are owned by company insiders. Comparatively, 31.6% of Equillium shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has better earnings & valuation, MDCX or EQ? Equillium has higher revenue and earnings than Medicus Pharma. Medicus Pharma is trading at a lower price-to-earnings ratio than Equillium, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMedicus PharmaN/AN/A-$11.16M-$1.16-2.68Equillium$41.10M0.36-$8.07M-$0.39-1.06 SummaryEquillium beats Medicus Pharma on 8 of the 15 factors compared between the two stocks. Get Equillium News Delivered to You Automatically Sign up to receive the latest news and ratings for EQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EQ vs. The Competition Export to ExcelMetricEquilliumMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.04M$2.96B$5.54B$9.41BDividend YieldN/A2.46%3.75%4.03%P/E Ratio-1.068.2821.0120.09Price / Sales0.36303.17433.8199.01Price / CashN/A42.5936.1658.27Price / Book0.777.678.125.65Net Income-$8.07M-$55.28M$3.25B$257.91M7 Day Performance18.60%2.50%0.97%2.09%1 Month Performance28.71%11.70%7.36%11.13%1 Year Performance-54.38%4.89%31.31%18.40% Equillium Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EQEquillium2.5681 of 5 stars$0.42-1.4%$3.00+622.7%-54.6%$15.04M$41.10M-1.0640MDCXMedicus Pharma2.5064 of 5 stars$3.40+0.6%$23.50+591.2%N/A$45.88MN/A-2.93N/AGap UpHigh Trading VolumeNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070APLTApplied Therapeutics4.5429 of 5 stars$0.34+4.9%$6.10+1,717.6%-91.7%$45.30M$460K-0.7830Positive NewsPLURPluri3.5764 of 5 stars$5.79+0.2%$12.00+107.3%-5.6%$45.28M$330K-1.05150Positive NewsGap DownPRLDPrelude Therapeutics3.7171 of 5 stars$0.81+1.6%$4.50+457.8%-86.8%$44.82M$7M-0.48120MURAMural Oncology3.4567 of 5 stars$2.48-3.9%$12.00+383.9%-28.4%$44.55MN/A-0.32119ATNMActinium Pharmaceuticals2.1347 of 5 stars$1.42-1.4%$4.00+181.7%N/A$44.30MN/A-1.0230Positive NewsSCLXScilex2.5935 of 5 stars$6.25-1.7%$455.00+7,180.0%-86.4%$44.21M$50.71M-0.2280Positive NewsGap UpGRCEGrace Therapeutics2.6051 of 5 stars$3.00-4.2%$12.00+300.0%N/A$43.28MN/A-3.37N/APositive NewsXCURExicure1.518 of 5 stars$6.47-4.6%N/A+2,395.1%$42.83M$500K-1.6950Positive NewsGap Up Related Companies and Tools Related Companies Medicus Pharma Competitors Nabriva Therapeutics Competitors Applied Therapeutics Competitors Pluri Competitors Prelude Therapeutics Competitors Mural Oncology Competitors Actinium Pharmaceuticals Competitors Scilex Competitors Grace Therapeutics Competitors Exicure Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EQ) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...GoldCo Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Equillium, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Equillium With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
